Oculus Innovative Sciences, Inc. Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Prevention and Treatment of Peritonitis With Microcyn® Technology

Published: Sep 11, 2012

PETALUMA, Calif., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products, today announced the issuance of new U.S. patent for the use of Microcyn® Technology in the prevention and treatment of peritonitis. In this application, Microcyn® can be delivered to the peritoneal cavity intra-operatively, laproscopically or transabdominally; and can be administered to peritoneal tissue already affected by peritonitis or tissue at risk of developing this infection.

Back to news